The impact of the recent AAP changes in palivizumab authorization on RSV-induced bronchiolitis severity and incidence

The impact of the recent AAP changes in palivizumab authorization on RSV-induced bronchiolitis severity and incidence

Abstract Following the most recent modification by the American Academy of Pediatrics, based on American studies on RSV epidemiology, the Italian Drug Agency (AIFA) decided to limit the total financial coverage of the palivizumab prescription by the National Health Service only to the < 29 wGA gr...

Full description

Bibliographic Details
Main Authors: Antonino Capizzi, Michela Silvestri, Andrea Orsi, Renato Cutrera, Giovanni A. Rossi, Oliviero Sacco
Format: Article
Language:English
Published: BMC 2017-08-01
Series:Italian Journal of Pediatrics
Subjects:
Palivizumab
Respiratory syncytial virus
Prophylaxis
Preterm
Online Access:http://link.springer.com/article/10.1186/s13052-017-0390-8

Internet

http://link.springer.com/article/10.1186/s13052-017-0390-8

Similar Items